Topic: PBMCs

In recent years, human-nature interactions are becoming a fundamental issue. Indeed, spending time in nature reduces stress and promotes mental well-being; however, the underlying biological mechanisms of action are still elusive. Major depressive disorder (MDD), one of the most prevalent and debilitating psychiatric diseases, is characterized by severe symptoms that negatively influence health perception. Unfortunately, even after antidepressant treatments, a high percentage of patients do not achieve a personal full recovery. Therefore, we decided to i) evaluate the biological, molecular and

Relapsing remitting multiple sclerosis (RRMS) hits around 85% MS patients. The main disease modifying therapies (DMTs) of this subtype are: Fingolimod (Gilenya), IFN-β A1(Rebif & Avonex), Teriflunomide(Aubagio), IFN-β 1B(β-feron) and Dimethyl Fumarate(Marovarex).The study aimed at: 1.Expression profiling of long non-coding RNA MALAT-1 in RRMS patients, MALAT1 knockdown and evaluating successful silencing of MALAT1 by specific siRNAs, 2.Expression profiling of Inflammasome components in RRMS patients and studying the impact of MALAT1-knock down on them, 3.Expression profiling of Calreticuli